Patient characteristics and Ab assessment after the second and third vaccinations
| . | All cases . | HMA alone . | HMA+veneto . | P . |
|---|---|---|---|---|
| Patient characteristics | ||||
| No. of pts | 46 | 24/46 (52) | 22/46 (48) | |
| Age, median (range), y | 74 (42-85) | 73 (47-85) | 75 (42-83) | ns |
| Hematologic cancer | ||||
| AML | 36 | 14 | 22 | |
| MDS High risk | 10 | 10 | 0 | |
| No. of HMA cycles at Vax (range) | 2 (1-22) | 2 (1-22) | 2 (1-14) | ns |
| Ab test post-second Vax | ||||
| No. of pts who received 2 Vax | 46/46 (100) | 24/24 (100) | 22/22 (100) | ns |
| No. of pts tested | 33/46 (72) | 17/24 (71) | 16/22 (73) | ns |
| Time between Vax and Ab dosage, median (range), mo | 4.3 (1-7.7) | 4.5 (1-6.1) | 4.2 (1-7.7) | ns |
| Pts with seroconversion* | 30/33 (91) | 16/17 (94) | 14/16 (88) | ns |
| Ab level, U/mL | ns | |||
| 1-100 | 14/33 (43) | 8/17 (47) | 6/16 (37.5) | |
| 101-1000 | 11/33 (33) | 7/17 (41) | 4/16 (25) | |
| >1000 | 5/33 (15) | 1/17 (6) | 4/16 (25) | |
| Ab test post-third Vax | ||||
| No. of pts who received 3 Vax | 24/46 (52) | 14/24 (58) | 10/22 (45) | ns |
| No. of pts tested | 24/24 (100) | 14/14 (100) | 10/10 (100) | ns |
| Time between Vax and Ab dosage, median (range), mo | 1.5 (0.5-2.5) | 2 (0.5-2.5) | 1.75 (0.5-2.5) | ns |
| Pts with seroconversion* | 23/24 (96) | 13/14 (93) | 10/10 (100) | ns |
| Ab level, U/mL | ns | |||
| 1-100 | 5/24 (21) | 2/14 (14) | 3/10 (30) | |
| 101-1000 | 4/24 (17) | 2/14 (14) | 2/10 (20) | |
| >1000 | 14/24 (58) | 9/14 (64) | 5/10 (50) | |
| . | All cases . | HMA alone . | HMA+veneto . | P . |
|---|---|---|---|---|
| Patient characteristics | ||||
| No. of pts | 46 | 24/46 (52) | 22/46 (48) | |
| Age, median (range), y | 74 (42-85) | 73 (47-85) | 75 (42-83) | ns |
| Hematologic cancer | ||||
| AML | 36 | 14 | 22 | |
| MDS High risk | 10 | 10 | 0 | |
| No. of HMA cycles at Vax (range) | 2 (1-22) | 2 (1-22) | 2 (1-14) | ns |
| Ab test post-second Vax | ||||
| No. of pts who received 2 Vax | 46/46 (100) | 24/24 (100) | 22/22 (100) | ns |
| No. of pts tested | 33/46 (72) | 17/24 (71) | 16/22 (73) | ns |
| Time between Vax and Ab dosage, median (range), mo | 4.3 (1-7.7) | 4.5 (1-6.1) | 4.2 (1-7.7) | ns |
| Pts with seroconversion* | 30/33 (91) | 16/17 (94) | 14/16 (88) | ns |
| Ab level, U/mL | ns | |||
| 1-100 | 14/33 (43) | 8/17 (47) | 6/16 (37.5) | |
| 101-1000 | 11/33 (33) | 7/17 (41) | 4/16 (25) | |
| >1000 | 5/33 (15) | 1/17 (6) | 4/16 (25) | |
| Ab test post-third Vax | ||||
| No. of pts who received 3 Vax | 24/46 (52) | 14/24 (58) | 10/22 (45) | ns |
| No. of pts tested | 24/24 (100) | 14/14 (100) | 10/10 (100) | ns |
| Time between Vax and Ab dosage, median (range), mo | 1.5 (0.5-2.5) | 2 (0.5-2.5) | 1.75 (0.5-2.5) | ns |
| Pts with seroconversion* | 23/24 (96) | 13/14 (93) | 10/10 (100) | ns |
| Ab level, U/mL | ns | |||
| 1-100 | 5/24 (21) | 2/14 (14) | 3/10 (30) | |
| 101-1000 | 4/24 (17) | 2/14 (14) | 2/10 (20) | |
| >1000 | 14/24 (58) | 9/14 (64) | 5/10 (50) | |
Unless otherwise noted, data are n (%) or n/N (%).
Ab, anti-Spike IgG Ab; ns, not significant; pts, patients; Vax, vaccination; veneto, venetoclax.
Ab level >0.8 U/mL.